Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 15,048 | 23,017 | 44,654 | NaN |
| Research and development | 80,737 | 88,652 | 300,209 | NaN |
| General and administrative | 34,843 | 33,075 | 86,725 | NaN |
| Interest income | 5,205 | 6,476 | 22,719 | NaN |
| Loss from equity method investment | NaN | 0 | NaN | NaN |
| Other segment information | 904 | 1,754 | -2,653 | NaN |
| Net loss | -96,231 | -95,786 | -101,324 | -215,584 |
| Depreciation and amortization | 2,202 | 2,380 | 2,415 | 4,972 |
| Gain on disposal of property and equipment | NaN | NaN | 0 | NaN |
| Loss (gain) on disposal of property and equipment | NaN | -527 | NaN | NaN |
| Accelerated amortization/impairment of right-of-use assets | NaN | 3,635 | 2,521 | NaN |
| Stock-based compensation | 13,479 | 16,739 | 19,604 | 43,876 |
| Accretion of investment discounts | 535 | 826 | 1,085 | 3,947 |
| Recognition of equity method investment intra-entity profit on sales | NaN | NaN | 0 | 0 |
| Change in fair value of investments, net | -904 | -3,552 | 3,439 | -786 |
| (recognition) deferral of equity method investment intra-entity profit on sales | NaN | 0 | NaN | NaN |
| Loss from equity method investment | NaN | 0 | NaN | NaN |
| Change in fair value of contingent consideration | NaN | 0 | NaN | NaN |
| Accounts receivable | -337 | -1,582 | -303 | 2,836 |
| Prepaid expenses and other current assets | 12,972 | 8,690 | 23,035 | -5,373 |
| Operating lease right-of-use assets | -8,411 | -8,294 | -8,641 | -16,151 |
| Other assets | 74 | -1,938 | -25,288 | 24,415 |
| Accounts payable | -1,420 | 6,959 | 3,459 | -4,431 |
| Accrued expenses | -11,947 | 9,027 | -715 | -13,583 |
| Deferred revenue | -6,660 | -13,980 | -4,907 | -9,224 |
| Operating lease liabilities | -12,840 | -4,636 | -4,625 | -45,690 |
| Net cash used in operating activities | -117,346 | -69,285 | -76,899 | -248,552 |
| Purchases of property and equipment | 79 | 126 | 29 | 974 |
| Purchases of marketable securities | 46,965 | 67,050 | 116,651 | 138,809 |
| Sales and maturities of marketable securities | 113,354 | 94,710 | 115,939 | 341,021 |
| Net cash provided by investing activities | 66,310 | 27,534 | -741 | 201,238 |
| Issuance of shares through employee stock purchase plan | NaN | 1,352 | 0 | 1,237 |
| Net proceeds from issuance of common stock | NaN | 128,175 | NaN | NaN |
| Proceeds from options exercised | NaN | 625 | 97 | 0 |
| Net proceeds from issuance of common stock through at-the-market offerings | -94,606 | NaN | 114,760 | 13,415 |
| Net cash provided by financing activities | 33,569 | 1,977 | 114,857 | 14,652 |
| Net decrease in cash, cash equivalents and restricted cash equivalents | -17,467 | -39,774 | 37,217 | -32,662 |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | 167,568 | 207,342 | 202,787 | NaN |
| Cash, cash equivalents and restricted cash equivalents, end of period | 150,101 | 167,568 | 207,342 | NaN |